- Home
- IKNA vs REFR Comparison
IKNA vs REFR Comparison
Compare IKNA & REFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- REFR
- Stock Information
- Founded
- IKNA 2016
- REFR 1965
- Country
- IKNA United States
- REFR United States
- Employees
- IKNA N/A
- REFR N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- REFR Multi-Sector Companies
- Sector
- IKNA Health Care
- REFR Miscellaneous
- Exchange
- IKNA Nasdaq
- REFR Nasdaq
- Market Cap
- IKNA 74.8M
- REFR 67.4M
- IPO Year
- IKNA 2021
- REFR N/A
- Fundamental
- Price
- IKNA $1.57
- REFR $1.63
- Analyst Decision
- IKNA Buy
- REFR
- Analyst Count
- IKNA 2
- REFR 0
- Target Price
- IKNA $3.00
- REFR N/A
- AVG Volume (30 Days)
- IKNA 399.7K
- REFR 26.9K
- Earning Date
- IKNA 11-07-2024
- REFR 11-07-2024
- Dividend Yield
- IKNA N/A
- REFR N/A
- EPS Growth
- IKNA N/A
- REFR N/A
- EPS
- IKNA N/A
- REFR N/A
- Revenue
- IKNA $659,000.00
- REFR $1,469,616.00
- Revenue This Year
- IKNA N/A
- REFR N/A
- Revenue Next Year
- IKNA N/A
- REFR N/A
- P/E Ratio
- IKNA N/A
- REFR N/A
- Revenue Growth
- IKNA N/A
- REFR 102.07
- 52 Week Low
- IKNA $1.22
- REFR $0.92
- 52 Week High
- IKNA $2.17
- REFR $2.41
- Technical
- Relative Strength Index (RSI)
- IKNA 42.72
- REFR 33.30
- Support Level
- IKNA $1.62
- REFR $1.59
- Resistance Level
- IKNA $1.94
- REFR $1.74
- Average True Range (ATR)
- IKNA 0.10
- REFR 0.12
- MACD
- IKNA -0.01
- REFR -0.01
- Stochastic Oscillator
- IKNA 16.85
- REFR 23.81
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. Its revenue source comes from the licensing of technology.